Matinas BioPharma Holdings, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020; filed March 29, 2021. This is an annual report, not a standalone fourth-quarter report. Matinas is a clinical-stage biopharmaceutical company with no product sales. Its strategy centers on its Rutgers-licensed lipid nanocrystal (LNC) delivery platform and finding a partner to advance LYPDISO.
Financial performance and position
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $0.16 million | $0.09 million |
| Research and development expense | $14.36 million | $11.23 million |
| General and administrative expense | $10.01 million | $7.78 million |
| Net loss | $22.45 million | $17.37 million |
| Net loss attributable to common shareholders | $23.24 million | $18.30 million |
| Basic and diluted loss per share | $0.12 | $0.13 |
| Cash used in operating activities | $17.37 million | $14.09 million |
- Revenue was research-grant and feasibility-study income, not product revenue; the filing reports no product sales. Conventional operating margins are not meaningful for this development-stage company.
- At year-end, cash and cash equivalents were $12.43 million and marketable securities were $46.25 million, totaling $58.68 million; restricted cash was an additional $0.34 million. Current assets were $61.55 million and current liabilities $3.57 million.
- Total liabilities were $7.24 million, primarily lease liabilities and accrued expenses. The filing reports no outstanding note payable at year-end; operating and finance lease liabilities had present values of approximately $3.70 million and $0.055 million, respectively.
- Financing activities provided $48.05 million, principally from a January 2020 public offering with $46.70 million in net proceeds. Investing activities used $40.67 million, largely reflecting purchases of marketable securities, rather than operating investment alone.
- Accumulated deficit reached $107.51 million. The company expects continuing losses and states year-end cash and marketable securities, plus approximately $5.6 million net proceeds from January 2021 ATM sales, should fund planned operations into 2024. This is a management estimate dependent on assumptions, not a guarantee.
Material changes and business developments
- Net loss widened by about $5.1 million year over year as R&D and G&A expenses increased. R&D rose approximately $3.1 million, including higher clinical/preclinical development and staffing costs.
- MAT2203: Oral LNC-formulated amphotericin B is being studied for cryptococcal meningitis in the NIH-supported EnACT trial. Cohort 1 progressed after unanimous DSMB recommendation; Cohort 2 was enrolling, with a readout expected in the second half of 2021. These are forward-looking expectations in the filing, not reported results. The candidate has QIDP/Fast Track designations for specified fungal indications and orphan designation for cryptococcosis.
- MAT2501: Oral LNC-formulated amikacin is under development for NTM lung disease. The Cystic Fibrosis Foundation awarded up to $4.2 million in November 2020 to support development through early clinical work; the filing describes positive mouse-model results and plans for toxicology studies and a single-ascending-dose study in 2021.
- LYPDISO: The company shifted away from internally pursuing a Phase 3 program for severe hypertriglyceridemia and is seeking a partner for further development, including potential cardiovascular-risk work. In ENHANCE-IT, the triglyceride primary endpoint was not statistically significant in the prespecified pharmacodynamic population, though it was significant in the per-protocol population; EPA levels were significantly higher versus Vascepa. Topline results were announced in February 2021, after fiscal year-end.
- Collaborations included research evaluations with ViiV Healthcare and Genentech, and a December 2020 NIAID collaboration to evaluate oral LNC formulations of Gilead’s remdesivir. These are early-stage evaluations, not established commercial revenue streams.
Outlook, risks, contingencies, and unusual items
- Management expects higher R&D spending in 2021. The company has no approved products, product-sales revenue, or sales and marketing infrastructure, and expects to need additional capital over time. Financing could dilute shareholders or require rights to be licensed to partners.
- Key risks include clinical and regulatory failure or delay; dependence on the Rutgers-licensed LNC technology; manufacturing and supplier constraints; reliance on NIH, CFF, CROs, and potential partners; competition; and protection of intellectual property. COVID-19 had no significant reported impact on FY2020 financial results, but future effects were uncertain.
- Potential dilution includes 22.55 million outstanding options and 1.33 million warrants at December 31, 2020, convertible Series B preferred stock, and up to 3.0 million contingent shares tied to LNC development milestones. Series B stock dividends are payable in common shares. Series A holders may receive contingent royalties on MAT2203/MAT2501 sales or licensing proceeds, subject to stated caps.
- The CFF MAT2501 award includes development conditions and potential repayment or licensing consequences if development is interrupted, as well as contingent royalties if the product is commercialized.
- Internal-control disclosure inconsistency: Risk-factor text says internal controls were ineffective and refers to an adverse auditor opinion, while Item 9A says the prior material weakness was remediated and controls were effective at year-end. The auditor’s report states it was not engaged to audit internal control and expresses no opinion on its effectiveness. This discrepancy warrants review.
- The filing reports no pending legal proceedings and no off-balance-sheet arrangements. It identifies research-and-development accrual estimates as a critical audit matter; the auditor cited judgment in estimating CRO service progress and milestone costs.
Most important facts to verify
- Whether the stated runway into 2024 remains valid after updated spending, trial timelines, and any subsequent financing.
- EnACT Cohort 2 results and the trial’s eventual design, enrollment, and regulatory relevance.
- Whether Matinas secures a LYPDISO partner, and how the mixed ENHANCE-IT endpoint results affect development plans.
- MAT2501 progress against CFF-funded milestones and the award’s contingent repayment, licensing, and royalty provisions.
- The correct status of internal-control remediation and the basis for the conflicting disclosures.
- Fully diluted share exposure, including preferred-stock conversion/dividends, outstanding options and warrants, and milestone shares.